lulizumab pegol for Kidney Transplant

"The age restriction for this trial is 18-70."

"Lulizumab pegol is a common treatment for lung cancer. However, lulizumab pegol can also serve as an effective intervention against advanced carcinoid tumor, ulcerative colitis, and varicella-zoster virus acute retinal necrosis."

"So far, this trial has enrolled patients from Northwestern Memorial Hospital: Transplantation in Chicago, Illinois; University of Alabama School of Medicine: Transplantation in Birmingham, Alabama; and University of Colorado (UC) Health Transplant Center - Anschutz in Aurora, Colorado. There are 7 other locations where recruitment is still ongoing."

"Based on a review of the information available on clinicaltrials.gov, it appears that this trial is not currently recruiting patients. This study was initially posted on December 11th, 2019 and last updated on October 31st, 2020. There are 745 other trials actively looking for patients right now."

"There are 730 ongoing clinical trials studying the efficacy of lulizumab pegol. Of these, 158 are Phase 3 studies. Most of the research for this medication is based in Philadelphia, but there are 23341 locations running trials worldwide."

"Up to 10 individuals between 18 and 70 years of age who have kidney disease may be accepted into this trial. In addition to meeting the general age and health requirements, participants must also use one of the following birth control methods for 12 months: Non-hormonal IUDs, Note: Female participants of childbearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for 12 months while on study drug regimen., Vasectomized partner, Male Participants-."

"Unfortunately, this study is no longer looking for patients that meet the necessary requirements. Although, there are 15 other trials involving kidney cancer and 730 trials utilising lulizumab pegol that currently have open enrollment."